Nephrocare Health Services Fair Value
Nephrocare Health Services (NEPHROPLUS) average fair value is ₹1626.22 across 4 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹649.7 (+150.3%), fair value range ₹75.41–₹2920.0. See NEPHROPLUS book value comparison to compare market price against book value per share.
Fair Value Analysis Export
NEPHROPLUS Fair Value vs Current Price — Valuation Summary
NEPHROPLUS average fair value, fair value range, price gap and valuation status across 4 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF). Examine Nephrocare Health Services quarterly earnings for recent quarterly revenue, profit and EPS trends.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Discounted Cash Flow (DCF)
NEPHROPLUS Fair Value Analysis — Data Sources & Coverage
Nephrocare Health Services financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit Nephrocare Health Services share price chart.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
NEPHROPLUS vs Healthcare Services Sector Peers — P/E, P/B & Market Cap
Nephrocare Health Services P/E ratio, P/B ratio and market capitalisation vs Healthcare Services sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jupiter Life Line Hospit… | JLHL | 44.49 | 5.79 | ₹8,320 |
| One Global Service Provi… | ONEGLOBAL | 13.34 | 8.2 | ₹872 |
| Suraksha Diagnostic | SURAKSHA | 40.64 | 5.71 | ₹1,356 |
| Gujarat Kidney and Super… | GKSL | 81.21 | 3.81 | ₹1,080 |
| Invicta Diagnostic | INVICTA | 23.99 | 2.21 | ₹107 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.